Ardelyx Inc ARDX

NAS: ARDX | ISIN: US0396971071   14/11/2024
4,710 USD (+4,67%)
(+4,67%)   14/11/2024

10 september 2024 · Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX · Persbericht

6 september 2024 · Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX · Persbericht

6 september 2024 · SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx · Persbericht

31 augustus 2024 · INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx · Persbericht

27 augustus 2024 · October 15, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ARDX · Persbericht

23 augustus 2024 · Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 - ARDX · Persbericht

25 oktober 2023 · Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance? · Persbericht

24 oktober 2023 · Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance? · Persbericht

20 oktober 2023 · Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics? · Persbericht

19 oktober 2023 · Thinking about buying stock in Ardelyx, RVL Pharmaceuticals, Wheeler Real Estate Investment Trust, Troika Media Group, or AT&T? · Persbericht

18 oktober 2023 · Thinking about buying stock in Tempest Therapeutics, VinFast Auto, AGNC Investment, Ardelyx, or Viking Therapeutics? · Persbericht

2 februari 2023 · Ardelyx, Inc. Reports Employment Inducement Grants · Persbericht

29 december 2022 · FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) · Persbericht

23 december 2022 · Ardelyx, Inc. Reports Employment Inducement Grants · Persbericht

17 december 2022 · Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis · Persbericht

22 november 2022 · Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference · Persbericht

17 november 2022 · Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis · Persbericht

16 november 2022 · Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis · Persbericht

4 november 2022 · National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels · Persbericht

3 november 2022 · Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights · Persbericht

Mijn selecties